Assessment of Endometrial and Sub-endometrial Vascularity Before and After PRP Infusion in Frozen Embryo Transfer Cycles

NCT04247204 | Unknown

• 1 other identifier: R.20.01.711
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

A good quality embryo and receptive endometrium are important aspects in achieving optimal outcomes in assisted reproductive treatment (ART). Endometrial thickness is an important marker of uterine receptivity. A thin endometrium defined by an endometrial thickness ≤7mm was reported as a poor factor associated with significantly lower implantation and pregnancy rates as well as a higher risk of miscarriage. Nowadays, platelet-rich plasma (PRP) intrauterine infusion is a promising approach for the treatment of refractory thin endometrium in patients undergoing frozen-thawed embryo transfer. This is based on its ability to stimulate proliferation and angiogenesis with a large number of growth factors and cytokines i.e. the endometrium becomes thicker, with higher vascularity. PRP is easily prepared from an autologous blood sample that eliminates the risk of immunological reactions and transmission infections at low cost. Endometrial blood flow is another important marker reflective of uterine receptivity. Although publications are increasing concerning the efficacy of PRP intrauterine infusion on endometrial expansion and proliferation in frozen-thawed embryo transfer cycles, yet its angiogenetic effects have not been evaluated so far in either thin endometrium or normal endometrium thickness. Our study aims to evaluate endometrial and sub-endometrial vasculature patterns before and after PRP infusion in frozen-thawed embryo transfer cycles with normal endometrium thickness.

Conditions

Frozen Embryo Transfer

Outcome Measures

Primary Outcomes (1)

• Vascularization index of the endometrial region

  Vascularization index of the endometrial region will be measured by a researcher using the built-in VOCAL (Virtual Organ Computer-Aided Analysis) software for 3D power Doppler analysis.

  Day 15 to 18 of the frozen embryo transfer cycle

Secondary Outcomes (5)

• Flow index of the endometrial region

  Day 15 to 18 of the frozen embryo transfer cycle

• Vascularization flow index of the endometrial region

  Day 15 to 18 of the frozen embryo transfer cycle

• Vascularization index of the sub-endometrial region

  Day 15 to 18 of the frozen embryo transfer cycle

• Flow index of the sub-endometrial region

  Day 15 to 18 of the frozen embryo transfer cycle

• Vascularization flow index of the sub-endometrial region

  Day 15 to 18 of the frozen embryo transfer cycle

Study Arms (1)

Platelet-rich plasma (PRP) intrauterine infusion

EXPERIMENTAL

Biological: Platelet-rich plasma intrauterine infusion

Interventions

Platelet-rich plasma intrauterine infusion BIOLOGICAL

For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.

Platelet-rich plasma (PRP) intrauterine infusion

Eligibility Criteria

• Age: 20 Years - 35 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Subfertile women undergoing frozen-thawed embryo transfer with at least previously failed one ICSI cycle.
• Age between 20-35 years.
• Women with endometrium thickness between 8-14 mm on D15 of the frozen embryo transfer cycle

You may not qualify if:

• Women with a thin endometrium (≤ 7 mm) on day 15 of the cycle.
• Women with known hematological or immunological disorders
• Women with uncontrolled endocrine or other medical conditions, such as hyperprolactinemia or thyroid diseases.
• Women with uterine abnormalities e.g. Asherman syndrome, myomas, uterine septum, bicornuate uterus.
• Women who refuse to participate in the study.

Sponsors & Collaborators

• Hatem AbuHashim: lead

Related Publications (1)

• Nandi A, Martins WP, Jayaprakasan K, Clewes JS, Campbell BK, Raine-Fenning NJ. Assessment of endometrial and subendometrial blood flow in women undergoing frozen embryo transfer cycles. Reprod Biomed Online. 2014 Mar;28(3):343-51. doi: 10.1016/j.rbmo.2013.11.004. Epub 2013 Nov 22.

  PMID: 24447958 BACKGROUND

Study Officials

• Hatem Abu Hashim, MD. FRCOG. PhD

  Faculty of Medicine, Mansoura University

  STUDY CHAIR

• Mohamed Taman, MD

  Faculty of Medicine, Mansoura University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hatem Abu Hashim, MD. FRCOG.PhD

CONTACT

+20502300002; hatem_ah@hotmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 24, 2020
• First Posted: January 29, 2020
• Study Start: February 8, 2020
• Primary Completion: August 31, 2020
• Study Completion: October 5, 2020
• Last Updated: January 29, 2020

Record last verified: 2020-01